Pharmaceutical Executive Daily: Zentalis Doses First Patient with Azenosertib in Phase III Trial

In today's Pharmaceutical Executive Daily, Bayer agrees to acquire Perfuse Therapeutics for up to $2.45 billion and Madrigal obtains an exclusive global license for a precision siRNA therapy targeting a key genetic driver of MASH, Zentalis Pharmaceuticals announces the first patient dosed in a Phase III trial and Brooke Ervin argues that translating real-world evidence into commercial and clinical impact in urology requires more than access to data.